Overview
Applied StemCell provides iPSC-derived cells, gene editing technologies like TARGATT™ and S-SELeCT™, and CRO/CDMO services for cell therapy development. They offer hypoimmunogenic hiPSCs, disease modeling, differentiation, and large DNA knock-ins up to 50 kb for precise genome engineering. Their products support drug screening, nonclinical studies, and GMP manufacturing from research to pre-IND stages.
Frequently asked questions
- What gene editing technologies does Applied StemCell offer?
- Applied StemCell offers TARGATT™ for large knock-ins up to 50 kb and S-SELeCT™ for precise site-specific gene insertions without free DNA breaks, enabling consistent protein expression and genome engineering in human iPSCs.
- What iPSC-derived products and services are available?
- They provide hypoimmunogenic hiPSCs (B2M/CIITA knockouts), neural cells like microglia, neurons, astrocytes, and services including iPSC generation, disease modeling, differentiation, library construction, and drug screening.
- What are the applications and regulatory support levels?
- Products support research-use-only (RUO) to early GMP manufacturing for cell therapy discovery, development, nonclinical studies, and pre-IND, with technologies ensuring clear IP paths for allogeneic therapeutics commercialization.